Down Syndrome and Malignancies: A Unique Clinical Relationship
Ana C. Xavier,Yubin Ge,Jeffrey W. Taub
DOI: https://doi.org/10.2353/jmoldx.2009.080132
2009-01-01
Abstract:The patterns of malignancies in Down syndrome (DS) are unique and highlight the relationship between chromosome 21 and cancer. DS children have a ∼10- to 20-fold higher risk for developing acute lymphoblastic leukemia and acute myeloid leukemia (AML), as compared with non-DS children, although they do not have a uniformly increased risk of developing solid tumors. DS children with acute lymphoblastic leukemia frequently experience higher levels of treatment-related toxicity and inferior event-free survival rates, as compared with non-DS children. DS children also develop AML with unique features and have a 500-fold increased risk of developing the AML subtype, acute megakaryocytic leukemia (AMkL; M7). Nearly 10% of DS newborns are diagnosed with a variant of AMkL, the transient myeloproliferative disorder, which can resolve spontaneously without treatment; event-free survival rates for DS patients with AMkL ranges from 80% to 100%, in comparison with <30% for non-DS children with AMkL. In addition, somatic mutations of the GATA1 gene have been detected in nearly all DS TMD and AMkL cases and not in leukemia cases in non-DS children. GATA1 mutations are key factors linked to both leukemogenesis and the high cure rates of DS AMkL patients. Identifying the mechanisms that account for the high event-free survival rates of DS AMkL patients may ultimately improve AML treatment as well. Examining leukemogenesis in DS children may identify factors linked to the general development of childhood leukemia and lead to potential new therapeutic strategies to fight this disease. The patterns of malignancies in Down syndrome (DS) are unique and highlight the relationship between chromosome 21 and cancer. DS children have a ∼10- to 20-fold higher risk for developing acute lymphoblastic leukemia and acute myeloid leukemia (AML), as compared with non-DS children, although they do not have a uniformly increased risk of developing solid tumors. DS children with acute lymphoblastic leukemia frequently experience higher levels of treatment-related toxicity and inferior event-free survival rates, as compared with non-DS children. DS children also develop AML with unique features and have a 500-fold increased risk of developing the AML subtype, acute megakaryocytic leukemia (AMkL; M7). Nearly 10% of DS newborns are diagnosed with a variant of AMkL, the transient myeloproliferative disorder, which can resolve spontaneously without treatment; event-free survival rates for DS patients with AMkL ranges from 80% to 100%, in comparison with <30% for non-DS children with AMkL. In addition, somatic mutations of the GATA1 gene have been detected in nearly all DS TMD and AMkL cases and not in leukemia cases in non-DS children. GATA1 mutations are key factors linked to both leukemogenesis and the high cure rates of DS AMkL patients. Identifying the mechanisms that account for the high event-free survival rates of DS AMkL patients may ultimately improve AML treatment as well. Examining leukemogenesis in DS children may identify factors linked to the general development of childhood leukemia and lead to potential new therapeutic strategies to fight this disease. Approximately 350,000 individuals in the United States have Down syndrome (DS) and the Center for Disease Control estimates that the incidence of DS occurs once in 733 live births in the United States (5429 new cases per year).1Improved national prevalence estimates for 18 selected major birth defects-United States, 1999–2001.MMWR Morb Mortal Wkly Rep. 2006; 54: 1301-1305PubMed Google Scholar Based on the prevalence and recognition of DS individuals in the general population, considerable resources have been directed toward studying the various phenotypic features of DS individuals including learning disabilities, congenital heart disease, early onset Alzheimer's disease, and high risk of developing leukemia. Although DS children have an increased risk of developing acute leukemias, there is no increased risk of solid tumors in DS individuals. These discrepancies highlight the relationship between chromosome 21 and cancer, and they will be the subject of this review. Several types of solid tumors, including lymphomas, retinoblastomas, and testicular germ cell tumors, have been reported to occur in DS individuals.2Satge D Schorderet DF Balmer A Beck-Popovic M Addor MC Beckmann JS Munier FL Association Down syndrome-retinoblastoma: a new observation.Ophthalmic Genet. 2005; 26: 151-152Crossref PubMed Scopus (13) Google Scholar3Hsiung Stripp DC Vaughn D Van Arsdalen K Whittington R Three cases of advanced seminoma and Down's syndrome: a possible association.Am J Clin Oncol. 2003; 26: 197-199Crossref PubMed Scopus (5) Google Scholar4Satge D Le Tourneau A Verger JP Lefort S Geneix A Malet P Diebold J Vekemans M A case report of Down syndrome and centroblastic lymphoma.Pathol Res Pract. 1996; 192: 1266-1269Crossref PubMed Scopus (16) Google Scholar However, large population-based and/or tumor registries have shown that solid tumors occur significantly less frequently in DS children and adults in comparison with individuals without trisomy 21. Among 2814 individuals from different age groups with DS registered in a Danish study, only 24 cases of solid tumors were identified, whereas 47.7 cases would have been expected.5Hasle H Clemmensen IH Mikkelsen M Risks of leukaemia and solid tumours in individuals with Down's syndrome.Lancet. 2000; 355: 165-169Abstract Full Text Full Text PDF PubMed Scopus (650) Google Scholar An analysis of 6724 patients with neuroblastoma comprising 54.1 million children reported from 11 European countries identified no cases of neuroblastoma among DS children, although at least five cases would have been expected (P = 0.0045).6Satge D Sasco AJ Carlsen NL Stiller CA Rubie H Hero B de Bernardi B de Kraker J Coze C Kogner P Langmark F Hakvoort-Cammel FG Beck D von der Weid N Parkes S Hartmann O Lippens RJ Kamps WA Sommelet D A lack of neuroblastoma in Down syndrome: a study from 11 European countries.Cancer Res. 1998; 58: 448-452PubMed Google Scholar The National Wilms Tumor Study registry reviewed 5854 Wilms tumor cases and did not identify any kidney tumors in DS children, though it was estimated that 7.6 to 9.9 cases would have been expected.7Olson JM Hamilton A Breslow NE Non-11p constitutional chromosome abnormalities in Wilms' tumor patients.Med Pediatr Oncol. 1995; 24: 305-309Crossref PubMed Scopus (69) Google Scholar A British registry of 11,000 childhood solid tumor cases, identified only seven tumors in DS children [lymphoma (3), teratoma (1), glioma (2), and fibrosarcoma (1)].8Narod SA Stiller C Lenoir GM An estimate of the heritable fraction of childhood cancer.Br J Cancer. 1991; 63: 993-999Crossref PubMed Scopus (221) Google Scholar Among DS adults, carcinomas occur less frequently than in the general population. Several European studies have reported lower than expected incidences of breast cancer in DS females. Among 1278 women with DS registered in the Danish Cytogenetic and Danish Cancer Registries, no cases of breast cancer were identified, while at least seven cases would have been expected (P = 0.0007).5Hasle H Clemmensen IH Mikkelsen M Risks of leukaemia and solid tumours in individuals with Down's syndrome.Lancet. 2000; 355: 165-169Abstract Full Text Full Text PDF PubMed Scopus (650) Google Scholar Five DS women with breast cancer were identified in a French Registry spanning a 24 year period, though 69 cases would have been expected. These clinical observations suggest that gene dosage imbalances caused by the presence of an extra copy of chromosome 21 may be protective effect against the development of certain malignancies in DS individuals. The S-100b protein (encoded by a chromosome 21-localized gene) is normally secreted by glial cells and non-neural cells of the peripheral system. It has been shown that S-100b protein can inhibit the growth and induce death of human and murine neuroblastoma cell lines.6Satge D Sasco AJ Carlsen NL Stiller CA Rubie H Hero B de Bernardi B de Kraker J Coze C Kogner P Langmark F Hakvoort-Cammel FG Beck D von der Weid N Parkes S Hartmann O Lippens RJ Kamps WA Sommelet D A lack of neuroblastoma in Down syndrome: a study from 11 European countries.Cancer Res. 1998; 58: 448-452PubMed Google Scholar,10Satge D A decreased incidence of neuroblastomas in Down syndrome and overproduction of S-100 b protein: an hypothesis.Med Hypothesis. 1996; 46: 393-399Abstract Full Text PDF PubMed Scopus (17) Google Scholar DS patients have higher blood levels of serum S-100b protein than controls, which may be one factor accounting for the low incidence of neuroblastoma in DS children.6Satge D Sasco AJ Carlsen NL Stiller CA Rubie H Hero B de Bernardi B de Kraker J Coze C Kogner P Langmark F Hakvoort-Cammel FG Beck D von der Weid N Parkes S Hartmann O Lippens RJ Kamps WA Sommelet D A lack of neuroblastoma in Down syndrome: a study from 11 European countries.Cancer Res. 1998; 58: 448-452PubMed Google Scholar The COL18A1 gene (localized to chromosome 21) encodes for the anti-angiogenic agent, endostatin, which inhibits angiogenesis and tumor development in human and animal models. Higher levels of serum endostatin in DS individuals may potentially contribute to the lower occurrence of solid tumors in this group.11Zorick TS Mustacchi Z Bando SY Zatz M Moreira-Filho CA Olsen B Passos-Bueno MR High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours.Eur J Hum Genet. 2001; 9: 811-814Crossref PubMed Scopus (137) Google Scholar Other candidate chromosome 21-localized genes include: i) The DSCR-1 gene (Down syndrome critical region 1), which blocks blood vessel formation and tumor progression in mice by inhibition of intracellular calcineurin signaling.12Minami T Horiuchi K Miura M Abid MR Takabe W Noguchi N Kohro T Ge X Aburatani H Hamakubo T Kodama T Aird WC Vascular endothelial growth factor- and thrombin-induced termination factor. Down syndrome critical region-1, attenuates endothelial cell proliferation and angiogenesis.J Biol Chem. 2004; 279: 50537-50554Crossref PubMed Scopus (195) Google Scholar ii)The ETS 2 oncogene, which has been shown to protect against the development of intestinal tumors in a mouse model of DS.13Sussan TE Yang A Li F Ostrowski MC Reeves RH Trisomy represses Apc(Min)-mediated tumours in mouse models of Down's syndrome.Nature. 2008; 451: 73-75Crossref PubMed Scopus (129) Google Scholar In contrast to the potential protective effect of an extra copy of chromosome 21 and the incidence of solid tumors in DS individuals, the presence of trisomy 21 is considered one of the most significant and identifiable risk factors for the development of acute leukemias. It is estimated that DS children have a 10- to 20-fold increased risk of developing acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) compared with non-DS children, such that approximately 1:100 to 1:150 DS children will develop leukemia.14Taub JW Relationship of chromosome 21 and acute leukemia in children with Down syndrome.J Pediatr Hematol Oncol. 2001; 23: 175-178Crossref PubMed Scopus (43) Google Scholar A number of epidemiology studies have been conducted by the Children's Oncology Group (COG) to identify the basis for the increased incidence of leukemia in DS children. The studies have failed to identify any association between infection,15Canfield KN Spector LG Robison LL Lazovich D Roesler M Olshan AF Smith FO Heerema NA Barnard DR Blair CK Ross JA Childhood and maternal infections and risk of acute leukaemia in children with Down syndrome: a report from the Children's Oncology Group.Br J Cancer. 2004; 91: 1866-1872Crossref PubMed Scopus (29) Google Scholar maternal or paternal preconception irradiation exposure,16Linabery AM Olshan AF Gamis AS Smith FO Heerema NA Blair CK Ross JA Exposure to medical test irradiation and acute leukemia among children with Down syndrome: a report from the Children's Oncology Group.Pediatrics. 2006; 118: e1499-e1508Crossref PubMed Scopus (17) Google Scholar or presence of congenital anomalies17Linabery AM Blair CK Gamis AS Olshan AF Heerema NA Ross JA Congenital abnormalities and acute leukemia among children with Down syndrome: a Children's Oncology Group study.Cancer Epidemiol Biomarkers Prev. 2008; 17: 2572-2577Crossref PubMed Scopus (12) Google Scholar and the risk of developing acute leukemias in DS children. Studies have suggested that vitamin use in the periconceptional period may be protective against the development of ALL in DS,18Ross JA Blair CK Olshan AF Robison LL Smith FO Heerema NA Roesler M Periconceptional vitamin use and leukemia risk in children with Down syndrome: a Children's Oncology Group study.Cancer. 2005; 104: 405-410Crossref PubMed Scopus (45) Google Scholar while maternal exposure to professional pest exterminations, pesticides or chemicals,18Ross JA Blair CK Olshan AF Robison LL Smith FO Heerema NA Roesler M Periconceptional vitamin use and leukemia risk in children with Down syndrome: a Children's Oncology Group study.Cancer. 2005; 104: 405-410Crossref PubMed Scopus (45) Google Scholar and maternal infertility19Puumala SE Ross JA Olshan AF Robison LL Smith FO Spector LG Reproductive history, infertility treatment, and the risk of acute leukemia in children with Down syndrome: a report from the Children's Oncology Group.Cancer. 2007; 110: 2067-2074Crossref PubMed Scopus (20) Google Scholar may potentially increase the risk of acute leukemias in DS children. In the future, epidemiological studies should document environmental exposures with the analysis of biological samples,20Lafiura KM Bielawski DM Posecion Jr, NC Ostrea Jr, EM Matherly LH Taub JW Ge Y Association between prenatal pesticide exposures and the generation of leukemia-associated T(8;21).Pediatr Blood Cancer. 2007; 49: 624-628Crossref PubMed Scopus (51) Google Scholar as well as correlate these findings with leukemia-specific gene mutations. A 4-year-old Caucasian boy with DS presented to the emergency room with worsening right leg pain and problems walking. On examination, the patient appeared to be in pain. There was no lymphadenopathy, though hepatosplenomegaly was present. The white blood cell (WBC) count was 7200/mm3, with 5% myelocytes, 4% metamyelocytes, 14% bands, 36% neutrophils, 38% lymphocytes, 2% monocytes, 1% basophils, and 3% nucleated red blood cells; the hemoglobin was 10.6g/dL with normal mean corpuscular volume, and the platelet count 330, 000/mm3. The LDH was 653 U/L (normal range from 100 to 225 units per L). Liver-function tests were within normal limits. The uric acid was 6.8 mg/dl (normal range from 3.5 to 7.2 mg/dl). Review of the peripheral smear showed the presence of lymphoblasts. A bone marrow aspirate was performed and revealed 80% L1 lymphoblasts. Immunophenotyping was consistent with CD-45 negative, CD-34 positive, B precursor ALL expressing CD-19, CD-22, CD-10, and HLA-DR. Cytogenetic demonstrated the presence of trisomy 21 without any additional cytogenetic abnormalities. The patient received chemotherapy treatment according to the Pediatric Oncology Group (POG) 9905 ALinC 17: Protocol for Patients with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia, consisting of 130 weeks of therapy. Despite receiving reduced dosing intermediate methotrexate (500 mg/m2 instead of 1000 mg/m2) during consolidation therapy, the patient experienced episodes of transient mucositis. The patient currently remains in remission, 18 months from the completion of his therapy. DS children are estimated to represent ∼2% of total ALL cases in children21Zeller B Gustafsson G Forestier E Abrahamsson J Clausen N Heldrup J Hovi L Jonmundsson G Lie SO Glomstein A Hasle H Acute leukaemia in children with Down syndrome: a population-based Nordic study.Br J Haematol. 2005; 128: 797-804Crossref PubMed Scopus (112) Google Scholar (Table 1). Interestingly, the two most common chromosomal/cytogenetic subgroups of childhood B-precursor ALL involve qualitative or quantitative abnormalities involving chromosome 21, suggesting a direct or indirect relationship between chromosome 21 and leukemogenesis. Hyperdiploid ALL, in which blast cells contain >50 chromosomes, uniformly contain three to four copies of chromosome 21, while the TEL-AML1 t(12;21)(p13;q22) translocation involves the AML1 oncogene localized to chromosome 21. These ALL subgroups represent ∼25% to 30% and ∼20% to 25% of all B-precursor ALL cases, respectively, and are considered the most favorable ALL subgroups with event-free survival (EFS) rates of >80%.22Pui CH Robison LL Look AT Acute lymphoblastic leukemia.Lancet. 2008; 371: 1030-1043Abstract Full Text Full Text PDF PubMed Scopus (1165) Google Scholar Despite this relationship between chromosome 21 and ALL in non-DS children, several studies have reported that hyperdiploid ALL and TEL-AML1 ALL occur at an equal23Steiner M Attarbaschi A Konig M Nebral K Gadner H Haas OA Mann G Equal frequency of TEL/AML1 rearrangements in children with acute lymphoblastic leukemia with and without Down syndrome.Pediatr Hematol Oncol. 2005; 22: 229-234Crossref PubMed Scopus (10) Google Scholar or lower frequencies in DS ALL patients.24Shah N Al-Ahmari A Al-Yamani A Dupuis L Stephens D Hitzler J Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with down syndrome.Pediatr Blood Cancer. 2008; 52: 14-19Crossref Scopus (31) Google Scholar25Arico M Ziino O Valsecchi MG Cazzaniga G Baronci C Messina C Pession A Santoro N Basso G Conter V Acute lymphoblastic leukemia and Down syndrome: presenting features and treatment outcome in the experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP).Cancer. 2008; 113: 515-521Crossref PubMed Scopus (43) Google Scholar26James R Lightfoot T Simpson J Moorman AV Roman E Kinsey S Acute leukemia in children with Down's syndrome: the importance of population based study.Haematologica. 2008; 93: 1262-1263Crossref PubMed Scopus (15) Google Scholar27Forestier E Izraeli S Beverloo B Haas O Pession A Michalova K Stark B Harrison CJ Teigler-Schlegel A Johansson B Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study.Blood. 2008; 111: 1575-1583Crossref PubMed Scopus (136) Google Scholar28Bassal M La MK Whitlock JA Sather HN Heerema NA Gaynon PS Stork LC Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952.Pediatr Blood Cancer. 2005; 44: 21-28Crossref PubMed Scopus (61) Google Scholar Interestingly, the supernumerary chromosomes found in DS children with hyperdiploid ALL are similar to the ones found in non-DS patients,27Forestier E Izraeli S Beverloo B Haas O Pession A Michalova K Stark B Harrison CJ Teigler-Schlegel A Johansson B Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study.Blood. 2008; 111: 1575-1583Crossref PubMed Scopus (136) Google Scholar suggesting similar pathogenesis between the two hyperdiploid subgroups of patients. The t(8;14) is the second most commonly found translocation in DS ALL, after t(12,21),27Forestier E Izraeli S Beverloo B Haas O Pession A Michalova K Stark B Harrison CJ Teigler-Schlegel A Johansson B Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study.Blood. 2008; 111: 1575-1583Crossref PubMed Scopus (136) Google Scholar,29Lundin C Heldrup J Ahlgren T Olofsson T Johansson B B-cell precursor t(8;14)(q11;q32)-positive acute lymphoblastic leukemia in children is strongly associated with Down syndrome or with a concomitant Philadelphia chromosome.Eur J Haematol. 2009; 82: 46-53Crossref PubMed Scopus (19) Google Scholar,30Whitlock JA Sather HN Gaynon P Robison LL Wells RJ Trigg M Heerema NA Bhatia S Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study.Blood. 2005; 106: 4043-4049Crossref PubMed Scopus (113) Google Scholar and certain translocations related to an adverse outcome, such as t(4,11), t(1.19), and t(9,22), are rarely found in DS ALL patients as well as the T-cell ALL phenotype.27Forestier E Izraeli S Beverloo B Haas O Pession A Michalova K Stark B Harrison CJ Teigler-Schlegel A Johansson B Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study.Blood. 2008; 111: 1575-1583Crossref PubMed Scopus (136) Google Scholar,30Whitlock JA Sather HN Gaynon P Robison LL Wells RJ Trigg M Heerema NA Bhatia S Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study.Blood. 2005; 106: 4043-4049Crossref PubMed Scopus (113) Google ScholarTable 1Clinical Features of Acute Leukemia in Down Syndrome (DS) and Non-DS ChildrenDS-ALLNon-DS-ALLDS-AMLNon-DS AMLTotal % of cases2%98%15%85%Age at diagnosisPeak 2–5 yearsPeak 2–7 years<4 yearsPeak: <1 year, and during adolescenceMajor predisposing risk factorsNoneNonePrior history of the transient myeloproliferative disorder (TMD)NoneCytogenetic subgroupsLower frequency of hyperdiploidy and TEL-AML1Hyperdiploidy (25%–30%)>90% are AMkL (M7)∼10% AMkLOccurrence of T-cellt(12,21) (20%–25%)ALL raret(1,19) (5%–6%)t(4,11) (2%)Associated somatic gene mutationJAK2 mutations (∼20%)TEL-AML1 fusion proteinGATA1 mutations (uniform)Wild-type GATA1E2A-PBX1 fusion proteinAF4-ALL1/MLL/HRX fusion proteinsTreatment toxicityExcessive toxicity to methotrexate Inreased frequency of infectionsChemotherapy associated myelosuppressionIncreased risk of anthracycline-related cardiotoxicityChemotherapy associated myelosuppressionCure rates∼65%70%–85%80%–100%50% (<30% for AMkL cases) Open table in a new tab A recently identified genetic mutation involving the JAK2 gene (Janus kinase 2; localized to chromosome 9p24) has been found in approximately 20% of DS ALL cases, resulting in the substitution of the conserved arginine at position 683 (JAK2R683).31Bercovich D Ganmore I Scott LM Wainreb G Birger Y Elimelech A Shochat C Cazzaniga G Biondi A Basso G Cario G Schrappe M Stanulla M Strehl S Haas OA Mann G Binder V Borkhardt A Kempski H Trka J Bielorei B Avigad S Stark B Smith O Dastugue N Bourquin JP Tal NB Green AR Izraeli S Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.Lancet. 2008; 372: 1484-1492Abstract Full Text Full Text PDF PubMed Scopus (276) Google Scholar,32Kearney L Gonzalez De Castro D Yeung J Procter J Horsley SW Eguchi-Ishimae M Bateman CM Anderson K Chaplin T Young BD Harrison CJ Kempski H Wai E So C Ford AM Greaves M Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia.Blood. 2009; 113: 646-648Crossref PubMed Scopus (149) Google Scholar JAK2 protein belongs to the JAK family of non-receptor tyrosine kinase proteins, which are essential for normal intracellular signaling of hematopoietic and growth factor receptors. Gain-of-function mutations of the JAK2 gene have been identified in a high proportion of adults with myeloproliferative disorder, including polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis.33Kilpivaara O Levine RL JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.Leukemia. 2008; 22: 1813-1817Crossref PubMed Scopus (92) Google Scholar However, JAK2R683 mutations have been found exclusively in patients with DS and ALL, and are probably related to leukemogenesis in this group of patients. Different JAK2 mutations have been rarely found in non-DS ALL patients, but they have not been described in DS AML patients.34Kratz CP Böll S Kontny U Schrappe M Niemeyer CM Stanulla M Mutational screen reveals a novel JAK2 mutation. L611S, in a child with acute lymphoblastic leukemia.Leukemia. 2006; 20: 381-383Crossref PubMed Scopus (59) Google Scholar Studies have shown that DS ALL patients typically have inferior EFS rates and a greater incidence of treatment-related mortalities.24Shah N Al-Ahmari A Al-Yamani A Dupuis L Stephens D Hitzler J Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with down syndrome.Pediatr Blood Cancer. 2008; 52: 14-19Crossref Scopus (31) Google Scholar25Arico M Ziino O Valsecchi MG Cazzaniga G Baronci C Messina C Pession A Santoro N Basso G Conter V Acute lymphoblastic leukemia and Down syndrome: presenting features and treatment outcome in the experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP).Cancer. 2008; 113: 515-521Crossref PubMed Scopus (43) Google Scholar26James R Lightfoot T Simpson J Moorman AV Roman E Kinsey S Acute leukemia in children with Down's syndrome: the importance of population based study.Haematologica. 2008; 93: 1262-1263Crossref PubMed Scopus (15) Google Scholar,28Bassal M La MK Whitlock JA Sather HN Heerema NA Gaynon PS Stork LC Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952.Pediatr Blood Cancer. 2005; 44: 21-28Crossref PubMed Scopus (61) Google Scholar In a recent Children's Cancer Group (CCG) trial, DS ALL patients treated on a high risk protocol had equivalent treatment outcomes compared with non-DS ALL patients.35Hastings C Whitlock JA La M Seibel N Improved outcome of children with Down syndrome (DS) and high risk acute lymphocytic leukemia (HR-ALL): A report of CCG-1961.Blood (Abstracts). 2007; : 586Google Scholar The lower frequency of DS ALL patients with favorable cytogenetics (eg, hyperdiploid and TEL-AML1), may partly account for the inferior outcomes in some studies in addition to treatment related mortalities.24Shah N Al-Ahmari A Al-Yamani A Dupuis L Stephens D Hitzler J Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with down syndrome.Pediatr Blood Cancer. 2008; 52: 14-19Crossref Scopus (31) Google Scholar25Arico M Ziino O Valsecchi MG Cazzaniga G Baronci C Messina C Pession A Santoro N Basso G Conter V Acute lymphoblastic leukemia and Down syndrome: presenting features and treatment outcome in the experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP).Cancer. 2008; 113: 515-521Crossref PubMed Scopus (43) Google Scholar26James R Lightfoot T Simpson J Moorman AV Roman E Kinsey S Acute leukemia in children with Down's syndrome: the importance of population based study.Haematologica. 2008; 93: 1262-1263Crossref PubMed Scopus (15) Google Scholar,28Bassal M La MK Whitlock JA Sather HN Heerema NA Gaynon PS Stork LC Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952.Pediatr Blood Cancer. 2005; 44: 21-28Crossref PubMed Scopus (61) Google Scholar Host factors may also account for the differences in toxicities. DS individuals without leukemia have functional deficiencies in B-cell, T-cell, and phagocytic cell systems.36Ugazio AG Maccario R Notarangelo LD Burgio GR Immunology of Down syndrome: a review.Am J Med Genet Suppl. 1990; 7: 204-212PubMed Google Scholar They also have a higher risk of dying from bacterial sepsis, as well as developing severe viral infections.37Garrison MM Jeffries H Christakis DA Risk of death for children with Down syndrome and sepsis.J Pediatr. 2005; 147: 748-752Abstract Full Text Full Text PDF PubMed Scopus (70) Google Scholar Additionally, the metabolism of drugs in DS patients may also be distinct. Indeed, earlier studies revealed evidence of excessive toxicity including mucositis with methotrexate therapy.38Peeters M Poon A Down syndrome and leukemia: unusual clinical aspects and unexpected methotrexate sensitivity.Eur J Pediatr. 1987; 146: 416-422Crossref PubMed Scopus (64) Google Scholar,39Blatt J Albo V Prin W Orlando S Wollman M Excessive chemotherapy-related myelotoxicity in children with Down syndrome and acute lymphoblastic leukaemia.Lancet. 1986; 2: 914Abstract PubMed Scopus (42) Google Scholar The reduced folate carrier gene (localized to 21q22) encodes the transmembrane protein that transports intracellularly reduced folates including 5-methylhydrofolate (the major dietary folate) and methotrexate.40Matherly LH Molecular and cellular biology of the human reduced folate carrier.Prog Nucleic Acid Res Mol Biol. 2001; 67: 131-162Crossref PubMed Google Scholar The increased expression of the reduced folate carrier gene in various body tissues of DS patients (eg, gastrointestinal tract) may result in increased intracellular methotrexate transport contributing to methotrexate toxicity of DS patients. A newborn baby girl with DS was admitted to the neonatal intensive care unit because of cyanosis and she was found to have Tetralogy of Fallot. Further laboratory investigation revealed a WBC count of 59,000/mm3, hemoglobin of 17 g/dl and platelets of 80,000/mm3. Review of the peripheral smear showed the presence of 80% of large blasts with very basophilic staining cytoplasm, cytoplasmic blebbing, and prominent nucleoli. Total and direct bilirubin levels and transaminase levels were within the normal range. Flow cytometry of the peripheral smear revealed an abnormal CD-45 dim population of blasts, which expressed CD-11B, CD-33, CD-34, CD-117, weakly expressed CD-4, CD-7, showed partial expression of CD-56, CD-40, CD-13, and platelet-associated antigens CD-41, CD-61, CD-36, CD-9, and glycophorin A. Peripheral blood cytogenetics demonstrated constitutional trisomy 21. A diagnosis of the transient myeloproliferative disorder (TMD) was made. TMD is an acute megakaryocytic leukemia (AMkL)-related disorder diagnosed in newborn DS babies based on the detection of megakaryoblasts in the peripheral blood and/or bone marrow. TMD megakaryoblasts have the same morphology and surface antigen expression as AMkL cel